Arthritis, Juvenile
Arthritis, Psoriatic
Arthritis, Rheumatoid
Colitis, Ulcerative
Spondylitis, Ankylosing

Golimumab

Golimumab, a human monoclonal antibody, belongs to the tumor necrosis factor alpha (TNF- ) blockers class. This medication binds to soluble and transmembrane forms of human TNF- , preventing binding with receptors. The FDA has approved golimumab for treating conditions such as moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis (AS), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pcJIA). This activity discusses key aspects of golimumab usage, including its mechanism of action, adverse event profile, and optimal management strategies for patients with these inflammatory conditions, particularly those unresponsive to first-line therapies. Healthcare professionals benefit from updated knowledge regarding golimumab administration, making informed decisions, and optimizing dosage regimens to reduce adverse reactions. This program improves patient outcomes by providing healthcare professionals with evidence-based guidance on treating RA, PA, UC, and pcJIA with golimumab. This activity provides healthcare professionals with information regarding the latest therapeutic advances, allowing for better management of these challenging conditions.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.